Antibody Therapeutic Development & Commercialization
BioTechLogic’s team of experts has deep expertise and experience working on the front lines of antibody therapeutic development.
The development of a successful antibody-based therapeutic requires the identification and creation of a selective and potent molecule that performs the needed action, humanization of sequences, affinity maturation, engineering to modulate effector functions, and addressing biophysical challenges that would negatively impact manufacturability and/or patient effectiveness.
Complete Antibody Therapy Product Lifecycle Support Services
BioTechLogic has extensive experience with antibody therapy development and commercialization, from preclinical to market. Whether choosing an antibody with the desired affinity and specificity for an antigen target, engineering an antibody to do the job, or selecting the appropriate expression system, we are here to help.
Antibody Development & Production
BioTechLogic has extensive experience supporting the development and production of monoclonal antibodies (mAbs), bispecific antibodies, antibody fragments, radiolabeled antibodies, antibody conjugates (ADC’s), and more.
How BioTechLogic Can Help
-
- Expression system selection
- Product characterization
- Analytical method development
- CDMO selection
-
- Critical Quality Attributes understanding
- Purification processes
- Reproducibility
- ADC conjugation development / optimization
-
- Upstream process development and scale-up
- Downstream process development and scale-up
- Regulatory filing support
Antibody Therapeutics CMC Services
CMC Strategy
Quality Assurance
Analytical Services
Regulatory Consulting & Submissions Support
Process Development & Validation
Contract Services & Tech Transfer Support
Supply Chain Management
Inspection Readiness
Project Management
Years
Consultants
Clients
projects
Antibody Therapeutic Resources
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.